Skip to main content
SpringerLink
Log in

Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Background

Subcutaneous recombinant interferon-beta 1a (IFN-β1a SC) is indicated for treatment of relapsing multiple sclerosis (RMS); however, it is associated with development of flu-like syndrome (FLS) in 75% of patients. No recommendations are available on whether evening or morning administration could induce better or worse FLS.

Objective

Primary objective was to investigate whether morning administration of IFN-β1a 44 µg (Rebif) would affect the severity of FLS versus evening administration, in patients with RMS. Secondary objectives were to investigate whether timing of administration could lead to a better quality of life.

Methods

Multicenter, open-label, 12-week, randomized, controlled, parallel-group, phase 4 study.

Results

Of 217 patients screened at 29 Italian sites, 200 were included in the study. Among these, 104 patients were randomized to IFN-β1a SC administration in the morning and 96 in the evening. Morning administration resulted in higher FLS scores, as measured by the Multiple Sclerosis Treatment Concern Questionnaire, at week 4 (p = 0.0083) and week 8 (p = 0.0079); however, the difference was no longer significant at the end of 12 weeks.

Conclusion

IFN-β1a evening injections in the first 8 weeks of treatment led to an improvement in FLS; when continuing therapy, time of administration could be decided according to patient’s lifestyle and preference.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Rae-Grant A, Day GS, Marrie RA et al (2018) Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90:789–800

    Article  Google Scholar 

  2. Ziemssen T, Ashtamker N, Rubinchick S et al (2017) Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. Expert Opin Drug Saf 16:247–255

    CAS  PubMed  Google Scholar 

  3. Moses H Jr, Brandes DW (2008) Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis. Curr Med Res Opin 24:2679–2690

    Article  CAS  Google Scholar 

  4. Gold R, Rieckmann P, Chang P et al (2005) The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol 12:649–656

    Article  CAS  Google Scholar 

  5. Plosker GL (2011) Interferon-β-1b: a review of its use in multiple sclerosis. CNS Drugs 25:67–88

    Article  CAS  Google Scholar 

  6. Maurelli M, Bergamaschi R, Antonini A et al (2018) Interferon-beta injection site reactions in patients with multiple sclerosis. J Dermatolog Treat 29:1–4

    Google Scholar 

  7. Landi D, Albanese M, Buttari F et al (2017) Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: results of a randomized, cross-over, placebo-controlled pilot study. PLoS One 12:e0165415

    Article  Google Scholar 

  8. Nadjar Y, Coutelas E, Prouteau P et al (2011) Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis. Clin Neurol Neurosurg 113:316–322

    Article  Google Scholar 

  9. Cramer JA, Cuffel BJ, Divan V et al (2006) Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand 113:156–162

    Article  CAS  Google Scholar 

  10. Devonshire V, Arbizu T, Borre B et al (2010) Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre. Phase IIIb study BMC Neurol 10:28

    Article  Google Scholar 

  11. Lugaresi A, Florio C, Brescia-Morra V et al (2012) Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. BMC Neurol 12:7

    Article  Google Scholar 

  12. Neilley LK, Goodin DS, Goodkin DE et al (1996) Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology 46:552–554

    Article  CAS  Google Scholar 

  13. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504

    Article  Google Scholar 

  14. Trufakin VA, Shurlygina AV (2016) Circadian rhythm in cytokines administration. Mini Rev Med Chem 16:55–66

    Article  CAS  Google Scholar 

  15. Kümpfel T, Schwan M, Pollmächer T et al (2007) Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients. Mult Scler 13:1138–1145

    Article  Google Scholar 

  16. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon- beta-1a in secondary progressive MS: clinical results. Neurology 56(11):1496–1504

    Article  Google Scholar 

  17. Kiyosawa K, Sodeyama T, Nakano Y et al (1989) Treatment of chronic non-A non-B hepatitis with human interferon beta: a preliminary study. Antivir Res 12:151–161

    Article  CAS  Google Scholar 

  18. Fujiwara K, Mochida S, Matsuo S (1998) Randomized control trial of interferon-β injections at 12-h intervals as a therapy for chronic hepatitis C. Hepatol Res 12:240–251

    Article  Google Scholar 

  19. PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group and University of British Columbia MS/MRI Analysis Group (2001) PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 56:1628–1636

    Article  Google Scholar 

  20. Kappos L, Traboulsee A, Constantinescu C et al (2006) Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 67:944–953

    Article  CAS  Google Scholar 

  21. Calabresi PA, Kieseier BC, Arnold DL et al (2014) Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol 13:657–665

    Article  CAS  Google Scholar 

  22. Taylor SJ, Pinnock H, Epiphaniou E et al. (2014) A rapid synthesis of the evidence on interventions supporting self-management for people with long-term conditions: PRISMS—practical systematic review of self-management support for long-term conditions. Health Services and Delivery Research No. 2.53

  23. Foley JF, Brandes DW (2009) Redefining functionality and treatment efficacy in multiple sclerosis. Neurology 72(Suppl 5):S1–S11

    Article  Google Scholar 

  24. Ehde DM, Bombardier CH (2005) Depression in persons with multiple sclerosis. Phys Med Rehabil Clin N Am 16:437–448

    Article  Google Scholar 

  25. Rae-Grant AD, Turner AP, Sloan A et al (2011) Self-management in neurological disorders: systematic review of the literature and potential interventions in multiple sclerosis care. J Rehabil Res Dev 48:1087–1100

    Article  Google Scholar 

  26. Butler E, Thomas R, Carolan A et al (2019) 'It's the unknown'—understanding anxiety: from the perspective of people with multiple sclerosis. Psychol Health 34:368–383

    Article  CAS  Google Scholar 

  27. Simmons RD (2010) Life issues in multiple sclerosis. Nat Rev Neurol 6:603–610

    Article  Google Scholar 

  28. Portaccio E, Amato MP (2009) Improving compliance with interferon-beta therapy in patients with multiple sclerosis. CNS Drugs 23:453–462

    Article  Google Scholar 

  29. Munschauer FE III, Kinkel RP (1997) Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 19:883–893

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the patients, investigators, co-investigators, and the study teams at each of the participating centers (List of Centers is provided in the Appendix).

Editorial assistance for the manuscript was provided by Dr. Ilaria Campo, on behalf of Editamed srl, Torino, Italy.

Funding

This study was sponsored by Merck Serono S.p.A., Rome, Italy; an affiliate of Merck KGaA, Darmstadt, German.

Author information

Authors and Affiliations

  1. Department G. F. Ingrassia, Neuroscience Section, University of Catania, Via Santa Sofia, 78, 95123, Catania, Italy

    Francesco Patti, Clara Grazia Chisari & Mario Zappia

  2. U.O.C. Neurology, Ospedale Generale Regionale “F. Miulli”, Acquaviva delle Fonti, BA, Italy

    Giovanni Bosco Zimatore

  3. Department of Neuroscience (NSRO), University of Naples Federico II, Napoli, Italy

    Vincenzo Brescia Morra

  4. Neurology Department, Hospital “Bianchi Melacrino Morelli”, Reggio Calabria, Italy

    Umberto Aguglia

  5. Multiple Sclerosis Center, Provincial Health Company of Cosenza, Cosenza, Italy

    Roberto Bruno Bossio

  6. Neurology Department, Emergency Hospital “Cannizzaro”, Catania, Italy

    Roberto Marziolo

  7. Neurology Department, University Hospital “Località Germaneto”, Catanzaro, Italy

    Paola Valentino

  8. Medical Affairs Department, Merck Serono S.p.A., Rome, Italy

    Antonio Capacchione

Authors
  1. Francesco Patti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni Bosco Zimatore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vincenzo Brescia Morra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Umberto Aguglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roberto Bruno Bossio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Roberto Marziolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Paola Valentino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Clara Grazia Chisari
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Antonio Capacchione
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mario Zappia
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

RELIEF Study Group

Corresponding author

Correspondence to Francesco Patti.

Ethics declarations

Conflicts of interest

GB Zimantore received travel funds and speaker honoraria from Sanofi-Genzyme, Novartis, Teva, Biogen, Almirall, Roche, Merck. A. Capacchione is an employee at Merck Serono, Italy, G.B. V. Brescia Morra has nothing to disclose. U. Aguglia has nothing to disclose. R. B. Bossio has nothing to disclose. R. Marziolo has nothing to disclose. P. Valentino has nothing to disclose. F. Patti received personal honararia for serving on advisor board Almirall, bayer, Biogen, Merck, Novartis, Roche and Sanofi; he further received research grants by Biogen, Merck, Fondazione Italiana Sclerosi Multipla and Reload Onlus. M. Zappia received travel grants by Biogen, Merck, Roche and Sanofi, personal compensation for speaking activities by Biogen and research grants by Biogen, Merck, Novartis and Sanofi. C.G. Chisari received travel and registration coverage for attending several national or international congresses or symposia from Almirall, Bayer Shering, Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, and TEVA.

Ethical standards

The authors obtained approval from the ethics committee of Azienda Ospedaliero-Universitaria “Policlinico Vittorio Emanuele,” Catania and subsequently from all other ethics committees of the participating centers.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 19 kb)

Appendix

Appendix

RELIEF study group

Azienda Ospedaliero- Universitaria Policlinico “Gaspare Rodolico” Clinica Nurologica I Via Santa Sofia 78, 95123 Catania

Coordinating center

Prof. Mario Zappia

Prof. Francesco Patti

Ospedale Clinicizzato SS Annunziata Centro SM—Clinica Neurologica

Via dei Vestini 66100 Chieti Scalo

Prof. Marco Onofrj

Presidio Ospedaliero degli Infermi di Biella SC di Neurologia Via Caraccio 5 13900 Biella

Dott. Lorenzo Capone

Azienda Ospedaliero- Universitaria Ospedali Riuniti Umberto I—G.M. Lancisi—G. Salesi

Via Conca 71

60126 Ancona

Dott.ssa Maura Danni

Osp. S. Eugenio di Roma Centro per la diagnosi e cura della SM U.O. di Neurologia P.le dell’Umanesimo 10–00144 Roma

Dott.ssa Daniela De Pascalis

Policlinico Universitario Torvergata- Neurologia

Dott.ssa Girolama Alessandra Marfia

Ospedale San Giuseppe Moscati

Viale Italia

83100 Avellino

Dott. Daniele Spitaleri

Azienda Ospedaliero Universitaria

Via Luigi Pinto 1

1–71100 Foggia

Prof. Carlo Avolio

Azienda Ospedaliera Cannizzaro Divisione di Neurologia

Via Messina 829

95126 Catania

Dott. Roberto Marziolo

Azienda Ospedaliera di Caserta Sant’Anna e San Sebastiano

Via Palasciano

81100 Caserta

Dott. Andrea Di Lauro

Azienda Ospedaliero-Universitaria Santa Maria della Misericordia

Clinica Neurologica

P.le Santa Maria della Misericordia 15

33100 Udine

Dott. Pierluigi Dolso

Ospedale di Circolo Fondazione Macchi

Neurologia e stroke

Via Borri 57

21100 Varese

Dott.ssa Paola Banfi

Ospedale Generale S. Giovanni Calibita-Fatebenefratelli

Dipartimento di Neuroscienze

Isola Tiberina 39

00186 Roma

Dott.ssa Maria Maddalena Filippi

Ospedale S. Donato

Via Pietro Nenni

Dott. Severi Sauro

Presidio Ospedaliero Sant’S.Elia Divisione di Neurologia Via Luigi Russo 6 93100 Caltanissetta

Dott. Michele Vecchio

Fondazione Istituto Neurologico Casimiro Mondino via Mondino,2 27100 Pavia

Dott. Roberto Bergamaschi

Azienda Ospedaliero-Universitaria "P. Giaccone"

Clinica Nurologica Via Del Vespro 129 90129 Palermo

Prof. Giuseppe Salemi

Azienda Ospedaliero-Universitaria San Martino

Largo R. Benzi 10

16132 Genova

Dott. Giuseppe Ribizzi

Az.Osp.Bianchi Melacrino Morelli U.O.Di Neurologia

Via Giuseppe Melacrino 21

89100 Reggio Calabria

Prof. Umberto Aguglia

ASP di Cosenza

U.O. di Neurologia

C.da Serraspiga

67100 Cosenza

Prof. Roberto Bruno Bossio

Ospedale G. Jazzolino

Piazza Fleming

89900 Vibo Valentia

Dott. Domenico Consoli

Ospedale A. Segni—U.O. Neurologia

Via Colle Cappuccini

Ozieri (SS)

Dott. Sebastiano Traccis

Azienda Ospedaliera Regionale San Carlo, Potenza

Prof. Gianmichele Malentacchi

Azienda Ospedaliero Universitaria “Federico II”

Via Pansini 5

80131 Napoli

Prof. Vincenzo Brescia Morra

Presidio Ospedaliero Dimiccoli

U.O. Neurologia

Via Ippocrate

70051 Barletta

Dott. Giovanni Bosco Zimatore

Ospedale P.A. Micone

U.O. di Neurologia

Via Oliva 22

16154 Genova—Sestri Ponente

Dott. Claudio Solaro

AO Citta della Salute e della Scienza di Torino

Neuroscienze

Via Cherasco 15

10126 Torino

Dott.ssa Paola Cavalla

Ospedale di Cattinara

Clinica Neurologica

Strada di Fiume 44

34138 Trieste

Dott. Antonio Bosco

Policlinico Universitario

Clinica Neurologica

Località Germaneto Catanzaro

Prof.ssa Paola Valentino

Ospedale Regina Montis Regalis

SC Neurologia—

via S. Rocchetto 99

12084 Mondovi CN

Dott. Franco Perla

Ospedale San Lazzaro

SC Neurologia

Via P. Belli 26—12051 Alba (CN)

Dott. Michele Dotta

Villa Mazzacorati

Centro SM

Via Toscana 158 Bologna

Dott. Sergio Stecchi

AUSL della Romagna

U.O. di Neurologia

Ospedale Santa Maria delle Croci

Viale Randi, 5

48121 Ravenna

Dott.ssa Maria Grazia Piscaglia

Azienda Nuovo Ospedale Garibaldi-Nesima Via Palermo 636, 95122 Catania

Dott. Davide Maimone

Campus Biomedico UO Neurologia,

Via Álvaro del Portillo, 200

00128 Roma

Prof. Vincenzo di Lazzaro

Azienda Ospedaliera di Rilievo Nazionale A. Cardarelli

U.O.S. Malattie Degenerative del S.N.C

Via A. Cardarelli 9

80131 Napoli

Dott. Ciro Florio

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patti, F., Zimatore, G.B., Brescia Morra, V. et al. Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study. J Neurol 267, 1812–1823 (2020). https://doi.org/10.1007/s00415-020-09771-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-020-09771-x

Keywords

Search

Navigation